Antidepressants for neuroprotection in Huntington's disease: A Review.
Moga, India. In Eur J Pharmacol, 25 Nov 2015
UNASSIGNED: Huntington Disease (HD), which is characterized by abnormal dance-like movements, is a neurodegenerative disorder caused by a genetic mutation that results in an expanded polyglutamine stretch in the NH2 terminus of huntingtin protein (HTT).
An Exploration of the Universe of Polyglutamine Structures.
Madrid, Spain. In Plos Comput Biol, 31 Oct 2015
Among them, a polyglutamine region that is present in huntingtin is known to exhibit a correlation between the length of the chain and the severity as well as the earliness of the onset of Huntington disease.
iPSC-Based Drug Screening for Huntington's Disease.
Novato, United States. In Brain Res, 28 Oct 2015
UNASSIGNED: Huntington's disease (HD) is an autosomal dominant neurodegenerative disorder, caused by an expansion of the CAG repeat in exon 1 of the huntingtin gene.
Targeting Hsp90/Hsp70-based protein quality control for treatment of adult onset neurodegenerative diseases.
In Annu Rev Pharmacol Toxicol, Dec 2014
Critical target proteins that unfold and aggregate in these diseases, such as the polyglutamine androgen receptor in spinal and bulbar muscular atrophy, huntingtin in Huntington's disease, α-synuclein in Parkinson's disease, and tau in Alzheimer's disease, are client proteins of heat shock protein 90 (Hsp90), and their turnover is regulated by the protein quality control function of the Hsp90/Hsp70-based chaperone machinery.